Osteoarthritis (OA) and related disorders
Leigh Callahan, PhD
University of North Carolina Thurston Arthritis Research Center
Chapel Hill, NC, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Ernest Vina, MD, MSc
University of Arizona
Tucson, AZ, United States
Disclosure(s): AstraZeneca: Grant/Research Support (Terminated, November 19, 2021)
These criteria are a major advancement in the field of vasculitis. Almost all clinical trials in AAV have essentially fully relied on use of a dichotomous outcome of relapse versus remission, and this outcome was based entirely on clinician-reported outcomes (CROs). The new criteria not only incorporates patients' perspectives, but also provides a gradation of response allowing for much greater utility for a range of clinical trials from early-phase proof of concept studies to late-phase labeling and label-extending trials.
Speaker: Leigh Callahan, PhD – University of North Carolina Thurston Arthritis Research Center
Speaker: Ernest Vina, MD, MSc – University of Arizona